Upstream Bio (NASDAQ:UPB) Rating Lowered to In-Line at Evercore

Upstream Bio (NASDAQ:UPB) was downgraded by analysts at Evercore from an “outperform” rating to an “in-line” rating in a note issued to investors on Friday, Marketbeat reports. They currently have a $15.00 target price on the stock. Evercore’s price target would suggest a potential upside of 73.01% from the stock’s current price.

A number of other equities analysts have also recently commented on UPB. Lifesci Capital began coverage on Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price target for the company. Mizuho raised Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Upstream Bio Price Performance

Shares of UPB opened at $8.67 on Friday. The firm has a 50-day moving average of $15.93 and a 200-day moving average of $21.37. Upstream Bio has a one year low of $5.14 and a one year high of $33.68. The company has a market cap of $468.52 million, a PE ratio of -3.25 and a beta of 2.96.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.52 million. Upstream Bio had a negative return on equity of 34.90% and a negative net margin of 5,026.03%. Analysts expect that Upstream Bio will post -4.3 earnings per share for the current year.

Institutional Trading of Upstream Bio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bain Capital Life Sciences Investors LLC lifted its position in Upstream Bio by 6.3% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after acquiring an additional 144,216 shares during the last quarter. Integral Health Asset Management LLC acquired a new position in shares of Upstream Bio in the third quarter valued at approximately $10,816,000. Geode Capital Management LLC grew its position in shares of Upstream Bio by 57.5% in the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after purchasing an additional 235,958 shares during the last quarter. Norges Bank bought a new position in shares of Upstream Bio during the second quarter worth approximately $10,650,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of Upstream Bio during the second quarter worth approximately $89,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.